TB-500 vs. BPC-157 Research Studies

The topic of this article will revolve around TB-500 vs. BPC-157 and the blend’s potential in research studies.

BPC-157 vs. TB-500

Studies suggest both BPC 157 and TB 500 may be powerful healing peptides, the characteristics and research applications of which have been the subject of many studies. Both are artificial variations of proteins found in nature that have had some of their most prominent properties artificially enhanced. Researchers speculate both peptides may boost immunity, speed up wound healing all across the body, and may even slow down the aging process. Although BPC 157 and TB 500 are not identical and do not perform identically, a comparison between the two is still appropriate. 

BPC 157 & TB 500 Peptide Blend and Wounds

TB 500 and BPC 157 have been studied extensively to explore their potential to accelerate wound healing and tissue restoration. Researchers hypothesise body protection compound (BPC) derivative BPC 157 may inhibit fibroblast proliferation and migration [i]. Fibroblasts are considered important for repairing the extracellular matrix. Research suggests similar results may be achieved by manipulating actin filaments using TB 500, a derivative of Thymosin beta-4 (T-4). The protein actin is essential for cell division and migration. TB 500 has been suggested to improve immune cell health, migration, and fibroblasts’ growth and migration rates.

BPC 157 & TB 500 Peptide Blend and Blood Vessels

Researchers speculate BPC 157 and TB 500 may both be strong angiogenesis promoters. Delivering immune and repair cells to an injured area requires a substantial network of blood arteries. Injuries to the musculoskeletal system, the cardiovascular system, and the nervous system all are considered to need the development of new blood vessels to heal.

The hormone vascular endothelial growth factor (VEGF) is considered responsible for the expansion of blood vessels. Studies suggest BPC 157 may increase the amount of VEGF receptors (called VEGFR2)[ii], [iii], whereas TB 500 may boost VEGF synthesis directly. Researchers hypothesise that although they do so in distinct ways, both peptides may promote the development of new blood vessels, which is essential to survival.

BPC 157 & TB 500 Peptide Blend and the Heart

Studies suggest TB 500 may exhibit additional impact in cardiovascular health simply because more studies have been conducted on it. TB 500 has been studied for over twenty years, and those studies have suggested several cardiovascular properties for the peptide. Researchers speculate that TB 500 may not only decrease inflammation and scarring that may contribute to long-term issues like heart failure [iv], but it may also promote the formation of collateral blood arteries that supply greater oxygen to vulnerable heart tissue [v].

Scientists hypothesise that BPC 157 also exhibits potential regarding heart health, but it hasn’t been studied nearly as extensively as TB 500. The potential antioxidant actions of BPC 157 may be among its most notable features. Research suggests the potent free radical malondialdehyde (MDA), a severe concern after a heart attack, may be neutralised by BPC 157.

Scientists speculate both peptides may potentially protect cardiovascular health, but TB 500 may be a better candidate due to the greater understanding of its role. Although both compounds have speculated some potential in animal studies, little is known about the potential cardiovascular properties of BPC 157.

BPC 157 & TB 500 Peptide Blend and Digestion

BPC was first isolated from gastric fluid. Fittingly, researchers speculate that BPC 157 may exert more impact in restoring the gastrointestinal system to health. Studies on BPC 157 have suggested that it may aid in the recovery from any gastrointestinal (GI) injury but may be especially helpful in the case of fistulas.

Although TB 500 did not come out on top in the analysis, its GI properties should not be overlooked. Studies suggest that combining antibiotic compounds with TB 500 has been suggested to significantly improved recovery rates from life-threatening bacterial infections [vi]. TB 500 seems to have a synergistic effect with certain antibiotics in the mitigation of potentially fatal illnesses. The recovery of the gastrointestinal system is frequently contingent on keeping the abdominal cavity free of pathogens. Therefore, studies suggest TB 500 might help reduce the risk of problems after GI procedures in test models.

More research is required to explore its potential in scientific research, and these studies must continue. Only academic and scientific institutions can use BPC-157 & TB-500 blend for sale. If you are a licensed academic interested in buying peptides for your clinical studies, visit the Biotech Peptides website. Please be aware that none of the items mentioned are approved for human or animal consumption. Laboratory research compounds are only for in-vitro and in-lab use. Any kind of physical introduction is illegal. Only authorised professionals and working scientists may make purchases. The content of this piece is intended only for instructional purposes. 

References 

[i] T. Huang et al., “Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro,” Drug Des. Devel. Ther., vol. 9, pp. 2485–2499, 2015, doi: 10.2147/DDDT.S82030.

[ii] K. N. Dubé and N. Smart, “Thymosin β4 and the vasculature: multiple roles in development, repair and protection against disease,” Expert Opin. Biol. Ther., vol. 18, no. sup1, Art. no. sup1, Jul. 2018, doi: 10.1080/14712598.2018.1459558.

[iii] M.-J. Hsieh et al., “Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation,” J. Mol. Med., vol. 95, no. 3, Art. no. 3, Mar. 2017, doi: 10.1007/s00109-016-1488-y.

[iv] K. M. Kassem, S. Vaid, H. Peng, S. Sarkar, and N.-E. Rhaleb, “Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?,” Can. J. Physiol. Pharmacol., vol. 97, no. 7, pp. 589–599, Jul. 2019, doi: 10.1139/cjpp-2018-0570.

[v] A. D. Shaghiera, P. Widiyanti, and H. Yusuf, “Synthesis and Characterisation of Injectable Hydrogels with Varying Collagen−Chitosan−Thymosin β4 Composition for Myocardial Infarction Therapy,” J. Funct. Biomater., vol. 9, no. 2, p. E33, Apr. 2018, doi: 10.3390/jfb9020033.

[vi] T. W. Carion et al., “Thymosin Beta-4 and Ciprofloxacin Adjunctive Therapy Improves Pseudomonas aeruginosa-Induced Keratitis,” Cells, vol. 7, no. 10, Art. no. 10, Oct. 2018, doi: 10.3390/cells7100145.

Sponsored